Perspective Therapeutics (CATX) Gross Margin (2010 - 2023)

Perspective Therapeutics (CATX) has 14 years of Gross Margin data on file, last reported at 20.6% in Q4 2023.

• For the quarter ending Q4 2023, Gross Margin changed N/A year-over-year to 20.6%; the trailing twelve-month figure through Dec 2023 stood at 54.73% (changed N/A YoY), and the FY2023 full-year result was 32.29%, changed N/A from the prior year.
• Gross Margin retreated to 20.6% in Q4 2023, from 33.78% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 59.24% in Q1 2020 to a low of 16.53% in Q2 2023.
• A 5-year average of 42.91% and a median of 45.69% in 2019 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin surged 1984 bps in 2019 and plunged 2718 bps in 2023, its largest moves.
• Tracing CATX's Gross Margin over 5 years: stood at 50.36% in 2019, then decreased by 2 bps to 49.47% in 2020, then fell by 12 bps to 43.32% in 2021, then retreated by 10 bps to 38.99% in 2022, then tumbled by 47 bps to 20.6% in 2023.
• Business Quant data shows CATX's Gross Margin at 20.6% in Q4 2023, 33.78% in Q3 2023, and 16.53% in Q2 2023.